OMass Therapeutics Overview
- Founded
- 2016
- Status
- Private
- Employees
- 31
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $3.87M
- Investors
- 4
OMass Therapeutics General Information
Description
Developer of a structural mass spectrometry technology platform intended to discover novel medicines. The company's platform offers access to native mass spectrometry without having to establish sophisticated instrumentation and expertise in-house, as well as provides a way to study complex protein assemblies and their interactions with other biological molecules, enabling biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics, within a dynamic and collaborative framework.
Contact Information
Website
Formerly Known As
OMass Technologies
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Primary Office
- The Schrödinger Building
- Heatley Road, The Oxford Science Park
- Oxford OX4 4GE
- England, United Kingdom
+44 01865 000000
OMass Therapeutics Timeline
OMass Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC | 21-Oct-2020 | $3.87M | 0000 | 000.00 | Completed | Generating Revenue |
| 3. Early Stage VC (Series A) | 13-Feb-2020 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 2. Early Stage VC (Series A) | 26-Jun-2018 | $18.6M | $21.7M | 000.00 | Completed | Generating Revenue |
| 1. Seed Round | 29-Mar-2016 | $3.07M | $3.07M | 00.000 | Completed | Startup |
OMass Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 | |
| A Ordinary | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Ordinary | 1,165,513 | $0.001290 | $1.29 | $1.29 | 1x | $1.29 | 8.03% |
OMass Therapeutics Executive Team (7)
OMass Therapeutics Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Dame Robinson | OMass Therapeutics | Co-Founder, Scientific Advisor & Board Member | 000 0000 |
| Edward Hodgkin Ph.D | Syncona | Chairman | 000 0000 |
| Jonathan Montagu | Self | Board Member | 000 0000 |
| Lachlan MacKinnon | Oxford Sciences Innovation | Board Member | 000 0000 |
| Magdalena Jonikas Ph.D | Syncona | Board Member | 000 0000 |
OMass Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialOMass Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Syncona | Venture Capital | Minority | 000 0000 | 000000 0 | |
| University of Oxford | Corporation | Minority | 000 0000 | 000000 0 | |
| Oxford Sciences Innovation | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Oxford Spin-out Equity Management | Venture Capital | Minority | 000 0000 | 000000 0 |
OMass Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000000 000000 | 25-Feb-2020 | 000000000000000000 | Biotechnology | 00000000 000000 |